New Menu Capability Now Available on VISION and VISION MAX
Analyzers Increases Confidence in Blood Transfusion-Related Test
Results
RARITAN, N.J., Sept. 27, 2021 /CNW/ -- Ortho Clinical
Diagnostics (NASDAQ: OCDX), one of the world's largest
pure-play in vitro diagnostics (IVD) companies, today announced the
availability of Immediate Spin Crossmatch (ISXM) on the company's
ORTHO VISION® and ORTHO VISION® MAX Analyzers
to aid in detecting incompatibility between donors and recipients
in blood transfusions.
ISXM is a serological test used in blood transfusions to detect
ABO blood type incompatibility between donor red blood cells and
recipient serum/plasma. While electronic crossmatch is becoming
more prevalent, many laboratories still perform full crossmatches
(AHG/IAT). When a full crossmatch is performed, it is required to
also complete an ISXM test.
"We're pleased to continue our legacy and tradition of bringing
relevant immunohematology assays to market to further enable
transfusion labs to perform critical tests needed for urgent
patient care. The availability of ISXM across all Ortho
platforms is a direct response to customer requests to improve
workflow and respond quickly to patient needs," said Andrew Corkum, head of Ortho's transfusion
medicine product portfolio. "We are proud to offer this new menu
capability to further ensure the ongoing safety of blood
transfusions while giving laboratory staff the ability to
streamline their facilities."
With the addition of ISXM, this new menu capability contributes
to Ortho's comprehensive automated testing portfolio. Ortho now has
the most comprehensive automated testing portfolio comprised of
crossmatching, an antibody panel, titrations and antigen
phenotyping. Most laboratories serviced by Ortho perform ISXM
manually. With ISXM available on the ORTHO VISION®
Platform, not only will laboratory staff now have increased
confidence in test results but can shift their focus on value-added
tasks and maximizing workflow processes.
The ABO blood group antigens have significant importance in
transfusion medicine, as they are the most immunogenic of all the
blood group antigens. According to the National Center for
Biotechnology Information (NBCI), clerical error is the most common
cause of death from a blood transfusion and occurs when an
incompatible type of ABO blood is transfused. ISXM adds another
layer to Ortho's industry-leading quality and safety measures,
helping to increase the reliability of test results.
Ortho Clinical Diagnostics is powered by Ortho Care® Service and Support, a
global, award-winning, holistic service and support program
designed to empower laboratorians to take full advantage of Ortho's
solutions and consistently deliver the highest quality care.
For more information about Ortho's automated testing solutions,
visit our website.
About Ortho Clinical Diagnostics
Ortho Clinical
Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play
in vitro diagnostics (IVD) companies dedicated to transforming
patient care.
More than 800,000 patients across the world are impacted by
Ortho's tests each day. Because Every Test Is A
LifeTM, Ortho provides hospitals, hospital networks,
clinical laboratories and blood banks around the world with
innovative technology to ensure test results are fast, accurate and
reliable. Ortho's customized solutions enhance clinical outcomes,
improve efficiency, overcome lab staffing challenges and reduce
costs.
From launching the first product to determine Rh+ or Rh- blood
type, developing the world's first tests for the detection of
antibodies against HIV and hepatitis C, introducing patented
dry-slide technology and marketing the first U.S. Food and Drug
Administration-authorized high-volume antibody and antigen tests
for COVID-19, Ortho has been a pioneering leader in the IVD space
for over 80 years.
The company is powered by Ortho
Care® Service and Support, an award-winning,
holistic program that ensures best-in-class technical, field and
remote service and inventory support to laboratories in more than
130 countries and territories around the globe.
For more information, visit Ortho's website or social
media channels: LinkedIn, Twitter, Facebook and YouTube.
References
Dean L. Blood Groups and Red Cell Antigens [Internet].
Bethesda (MD): National Center for
Biotechnology Information (US); 2005. Chapter 5, The ABO blood
group. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK2267/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ortho-clinical-diagnostics-announces-launch-of-new-isxm-capabilities-301385025.html
SOURCE Ortho Clinical Diagnostics